CIZZLE BIOTECHNOLOGY HOLDINGS PLC Cizzle Biotechnology Holdings Plc Share Price
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.675 GBX | 0.00% |
|
0.00% | -14.10% |
| 30/04 | EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down | AN |
| 30/04 | Cizzle Biotechnology Holdings Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 70.95L 90.29L 75Cr |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | -10L -12.73L -11Cr | EV / Sales 2022 | - |
| Net cash position 2022 | 5L 6L 5.06Cr | Net cash position 2023 | 15.57L 19.81L 16Cr | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.63
x | P/E ratio 2023 |
-4.04
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.88% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | +1.52% | ||
| 1 month | +1.52% | ||
| 3 months | -27.17% | ||
| 6 months | -18.29% | ||
| Current year | -14.10% |
1 week
1.60
1.80
1 month
1.571.85
Current year
1.573.38
1 year
1.573.38
3 years
1.308.25
5 years
1.3013.00
10 years
1.3013.00
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lee
DFI | Director of Finance/CFO | 63 | 14/21/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dawn Coverley
BRD | Director/Board Member | 59 | 14/21/14 |
Nigel Lee
DFI | Director of Finance/CFO | 63 | 14/21/14 |
John Treacy
BRD | Director/Board Member | 42 | 29/19/29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/24/22 | 1.675 | 0.00% | 222,236 |
| 21/24/21 | 1.675 | 0.00% | 87,584 |
| 20/24/20 | 1.675 | 0.00% | 153,570 |
| 17/24/17 | 1.675 | 0.00% | 473,742 |
| 16/24/16 | 1.675 | 0.00% | 237,217 |
Delayed Quote London S.E., May 22, 2024 at 09:05 pm IST
More quotes
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.10% | 84.5L | |
| +64.23% | 6.26TCr | |
| -2.31% | 4.12TCr | |
| +44.36% | 4.03TCr | |
| -8.29% | 2.79TCr | |
| +11.97% | 2.62TCr | |
| -21.16% | 1.91TCr | |
| +7.54% | 1.31TCr | |
| +27.17% | 1.21TCr | |
| +25.72% | 1.23TCr |
- Stock Market
- Equities
- PSL Stock
